Non-valvular atrial fibrillation Vitamin K antagonists New Oral Anticoagulants
Conditions
Interventions
Patients randomized to receive VKA will continue their treatment according to usual care, managed by the Thrombosis Service using a therapeutic range of INR 2.0-3.5. Patients randomized to NOAC therap
Sponsors
University Medical Centre Groningen
Eligibility
Inclusion criteria
Inclusion criteria: -Men or women aged >= 18 years who are currently treated with VKA for non-valvular atrial fibrillation, managed by the Groningen Thrombosis Service. -A minimum duration of 6 months of VKA treatment at the time of selection by the Thrombosis Service. - An individual Time in Therapeutic Range (iTTR) >= 70% over the 4 months of VKA treatment before selection by the Thrombosis Service.
Exclusion criteria
Exclusion criteria: -A thrombo-embolic event or major bleeding ever while on VKA. -Indication for anticoagulation other than atrial fibrillation. -Contra-indication to receive any kind of NOAC. -Life expectancy <1 year.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Net clinical benefit: composite of stroke, systemic embolism, myocardial infarction, vascular death and major bleeds. All components will also individually be assessed. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Efficacy - Safety - Burden of complications - Treatment expectations and satisfaction - Compliance - Quality of life - Feasibility | — |
Contacts
Public ContactJasper (J.H.A.) van Miert
UMCG
Outcome results
None listed